-
Je něco špatně v tomto záznamu ?
Serum biomarkers and their relationship to axial spondyloarthritis associated with inflammatory bowel diseases
L. Ondrejčáková, M. Gregová, K. Bubová, L. Šenolt, K. Pavelka
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, přehledy
- MeSH
- ankylózující spondylitida krev diagnóza imunologie MeSH
- axiální spondyloartritida krev diagnóza MeSH
- biologické markery * krev MeSH
- C-reaktivní protein analýza metabolismus MeSH
- HLA-B27 antigen genetika imunologie MeSH
- idiopatické střevní záněty * krev imunologie diagnóza komplikace MeSH
- leukocytární L1-antigenní komplex krev MeSH
- lidé MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Spondyloarthritis (SpA) constitute a group of chronic inflammatory immune-mediated rheumatic diseases characterized by genetic, clinical, and radiological features. Recent efforts have concentrated on identifying biomarkers linked to axial SpA associated with inflammatory bowel disease (IBD), offering predictive insights into disease onset, activity, and progression. Genetically, the significance of the HLA-B27 antigen is notably diminished in ankylosing spondylitis (AS) associated with IBD, but is heightened in concurrent sacroiliitis. Similarly, certain polymorphisms of endoplasmic reticulum aminopeptidase (ERAP-1) appear to be involved. Carriage of variant NOD2/CARD15 polymorphisms has been demonstrated to correlate with the risk of subclinical intestinal inflammation in AS. Biomarkers indicative of pro-inflammatory activity, including C-reactive protein (CRP) along with erythrocyte sedimentation rate (ESR), are among the consistent predictive biomarkers of disease progression. Nevertheless, these markers are not without limitations and exhibit relatively low sensitivity. Other promising markers encompass IL-6, serum calprotectin (s-CLP), serum amyloid (SAA), as well as biomarkers regulating bone formation such as metalloproteinase-3 (MMP-3) and Dickkopf-related protein 1 (DKK-1). Additional candidate indicators of structural changes in SpA patients include matrix metalloproteinase-3 (MMP-3), vascular endothelial growth factor (VEGF), tenascin C (TNC), and CD74 IgG. Fecal caprotein (f-CLP) levels over long-term follow-up of AS patients have demonstrated predictive value in anticipating the development of IBD. Serologic antibodies characteristic of IBD (ASCA, ANCA) have also been compared; however, results exhibit variability. In this review, we will focus on biomarkers associated with both axial SpA and idiopathic intestinal inflammation, notably enteropathic spondyloarthritis.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24014565
- 003
- CZ-PrNML
- 005
- 20240905133933.0
- 007
- ta
- 008
- 240725s2024 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.autrev.2023.103512 $2 doi
- 035 __
- $a (PubMed)38168574
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Ondrejčáková, L $u Institute of Rheumatology, Prague, Czech Republic; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 245 10
- $a Serum biomarkers and their relationship to axial spondyloarthritis associated with inflammatory bowel diseases / $c L. Ondrejčáková, M. Gregová, K. Bubová, L. Šenolt, K. Pavelka
- 520 9_
- $a Spondyloarthritis (SpA) constitute a group of chronic inflammatory immune-mediated rheumatic diseases characterized by genetic, clinical, and radiological features. Recent efforts have concentrated on identifying biomarkers linked to axial SpA associated with inflammatory bowel disease (IBD), offering predictive insights into disease onset, activity, and progression. Genetically, the significance of the HLA-B27 antigen is notably diminished in ankylosing spondylitis (AS) associated with IBD, but is heightened in concurrent sacroiliitis. Similarly, certain polymorphisms of endoplasmic reticulum aminopeptidase (ERAP-1) appear to be involved. Carriage of variant NOD2/CARD15 polymorphisms has been demonstrated to correlate with the risk of subclinical intestinal inflammation in AS. Biomarkers indicative of pro-inflammatory activity, including C-reactive protein (CRP) along with erythrocyte sedimentation rate (ESR), are among the consistent predictive biomarkers of disease progression. Nevertheless, these markers are not without limitations and exhibit relatively low sensitivity. Other promising markers encompass IL-6, serum calprotectin (s-CLP), serum amyloid (SAA), as well as biomarkers regulating bone formation such as metalloproteinase-3 (MMP-3) and Dickkopf-related protein 1 (DKK-1). Additional candidate indicators of structural changes in SpA patients include matrix metalloproteinase-3 (MMP-3), vascular endothelial growth factor (VEGF), tenascin C (TNC), and CD74 IgG. Fecal caprotein (f-CLP) levels over long-term follow-up of AS patients have demonstrated predictive value in anticipating the development of IBD. Serologic antibodies characteristic of IBD (ASCA, ANCA) have also been compared; however, results exhibit variability. In this review, we will focus on biomarkers associated with both axial SpA and idiopathic intestinal inflammation, notably enteropathic spondyloarthritis.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a biologické markery $x krev $7 D015415
- 650 12
- $a idiopatické střevní záněty $x krev $x imunologie $x diagnóza $x komplikace $7 D015212
- 650 _2
- $a axiální spondyloartritida $x krev $x diagnóza $7 D000089183
- 650 _2
- $a HLA-B27 antigen $x genetika $x imunologie $7 D015796
- 650 _2
- $a ankylózující spondylitida $x krev $x diagnóza $x imunologie $7 D013167
- 650 _2
- $a leukocytární L1-antigenní komplex $x krev $7 D039841
- 650 _2
- $a C-reaktivní protein $x analýza $x metabolismus $7 D002097
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Gregová, M $u Institute of Rheumatology, Prague, Czech Republic; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Bubová, K $u Institute of Rheumatology, Prague, Czech Republic; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic. Electronic address: bubova@revma.cz
- 700 1_
- $a Šenolt, L $u Institute of Rheumatology, Prague, Czech Republic; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic. Electronic address: senolt@revma.cz
- 700 1_
- $a Pavelka, K $u Institute of Rheumatology, Prague, Czech Republic; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 773 0_
- $w MED00008572 $t Autoimmunity reviews $x 1873-0183 $g Roč. 23, č. 3 (2024), s. 103512
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38168574 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905133927 $b ABA008
- 999 __
- $a ok $b bmc $g 2143997 $s 1226431
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 23 $c 3 $d 103512 $e 20231231 $i 1873-0183 $m Autoimmunity reviews $n Autoimmun Rev $x MED00008572
- LZP __
- $a Pubmed-20240725